Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Leiomyosarcoma × olaparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 46 Breast Neoplasms 39 Triple Negative Breast Neoplasms 19 Prostatic Neoplasms 18 Neoplasms 13 Fallopian Tube Neoplasms 13 Endometrial Neoplasms 12 Pancreatic Neoplasms 9 Recurrence 8 Neoplasm Metastasis 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Lung Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Glioma 5 Glioblastoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Carcinoma, Squamous Cell 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Stomach Neoplasms 3 Solid Tumor 3 Melanoma 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2

Interventions

Gemcitabine 15 Doxorubicin 8 Docetaxel 8 Radiotherapy 7 Trabectedin 6 Nivolumab 5 pazopanib 4 liposomal doxorubicin 3 Sunitinib 3 Dacarbazine 3 pembrolizumab 2 eribulin 2 durvalumab 2 avelumab 2 Specimen Handling 2 Radiation Dose Hypofractionation 2 Letrozole 2 Ifosfamide 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tremelimumab 1 temsirolimus 1 sotigalimab 1 selinexor 1 sargramostim 1 rucaparib 1 ribociclib 1 regorafenib 1 pegfilgrastim 1 olaratumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03851614 2026-02-09

DAPPER

University Health Network, Toronto

Phase 2 Active not recruiting

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡